People

Stuart M. Falber

Partner

Co-Chair, Life Sciences Group

Falber, Stuart M.

Stuart Falber represents clients in the life sciences area. For more than 20 years, Mr. Falber has served as counsel for a broad range of life sciences clients, ranging from startup private companies to mature public companies, investment banks and venture capital funds.

Mr. Falber's practice focuses on corporate and securities law, with an emphasis on private and public company counseling; representation of issuers, investment banks and investors in venture capital transactions, public offerings and other financing transactions; mergers and acquisitions, including public and private company acquisitions and dispositions, asset acquisitions and sales, and public and private company spinoffs; and corporate collaborations and licensing transactions.

Learn more about Mr. Falber's practice and how he can support your startup on WilmerHaleLaunch.com.

Recent Highlights

Representative transactions in which Mr. Falber has served as counsel include:

Venture Capital Transactions

  • Aileron Therapeutics, Inc. in its $48 million Series E financing rounds
  • Apellis Pharmaceuticals, Inc. in its $47 million Series D financing round
  • Celtaxsys, Inc. in its $40 million Series D financing round
  • Tokai Pharmaceuticals, Inc. in its 35.5 million Series E financing round
  • Trevi Therapeutics, Inc. in its $26 million Series B financing round

Public Offerings

  • Argos Therapeutics, Inc. in its $49.6 million initial public offering
  • Epizyme in multiple follow-on public offerings, including its $137.7 million public offering in January 2016
  • Idera Pharmaceuticals, Inc. in multiple follow-on public offerings, including its $86.25 million public offering in January 2015
  • The Medicines Company in a follow-on public offering raising a total of $201.2 million
  • Tetraphase Pharmaceuticals, Inc. in its $80.5 million initial public offering and in multiple follow-on public offerings, including its $173.1 million public offering in March 2015
  • Tokai Pharmaceuticals in its $105.3 million initial public offering

Merger and Acquisition Transactions

  • The Medicines Company in its acquisition of Incline Therapeutics for up to $390 million, including contingent payments
  • Penwest Pharmaceuticals Co. in its sale to Endo Pharmaceuticals, Inc. for $144 million
  • Gloucester Pharmaceuticals, Inc. in its sale to Celgene, Inc. for up to $640 million, including contingent payments
  • Transkaryotic Therapies, Inc. in its sale to Shire Pharmaceuticals Group plc for $16 billion

PIPE and 144A Transactions

  • The Medicines Company in 144A convertible note offerings, including its $350 million offering in January 2015
  • Argos Therapeutics, Inc. in its $60 million PIPE transaction
  • Idera Pharmaceuticals, Inc. in PIPE transactions raising a total of $17 million
  • New Leaf Ventures  in a PIPE transaction by MEI Pharma, Inc. raising a total of $27.5 million

Corporate Collaborations and Licensing Transactions

  • ZIOPHARM Oncology, Inc., Braintree Laboratories, Inc. and Idera Pharmaceuticals, Inc. in various licensing transactions

 

Professional Activities

Mr. Falber is a member of the American Bar Association, the Massachusetts Bar Association and the Boston Bar Association.

Honors & Awards

Publications & News

View

May 16, 2017

Finding a Way Through a Tight Deal Space

WilmerHale's Life Sciences Group Co-Chairs Belinda Juran and Stuart Falber share trends they are seeing in the life sciences industry regarding acquisitions and IPOs in an interview with Breaking Media's Above the Law.

December 28, 2016

WilmerHale Counsels Tokai Pharmaceuticals in Share Purchase Agreement with Otic Pharma

The WilmerHale deal team included Partners Hal Leibowitz, Stuart Falber, Belinda Juran, Bill Caporizzo and Amy Null; Counsel Michael Welhouse; Senior Associate Ryan Mitteness; and Associate Andrea Sorrentino.

August 15, 2016

WilmerHale Lawyers Named Among the 2017 Best Lawyers in America®, Six Recognized as Lawyers of the Year

Best Lawyers in America®—a respected peer-review publication in the legal industry—recognizes 101 WilmerHale lawyers and names six partners as Lawyers of the Year in its 23rd edition.

July 28, 2016

WilmerHale Advises Argos Therapeutics in Pricing of $50M Public Offering

Argos Therapeutics, Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, announced the pricing of its public offering of $50 million.

June 22, 2016

The Legal 500 United States 2016 Recognizes 111 WilmerHale Lawyers Across 30 Practice Areas

The guide's rankings are based on a series of criteria, including client feedback, interviews with private practice lawyers, and its own research.

May 12, 2016

WilmerHale Reps Spring Bank Pharmaceuticals in IPO

WilmerHale represented Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, in its initial public offering.

March 14, 2016

M&A: The Last Refuge For Biotechs Seeking Funding

WilmerHale's Life Sciences Group Co-Chairs Belinda Juran and Stuart Falber are interviewed by MedCity News—published by Breaking Media which, earlier this year, ranked the firm among the top three Best Life Sciences Law Firms for 2016 in its inaugural Life Science Index.

January 14, 2016

Epizyme Inc. Closes Follow-On Offering

WilmerHale represented Epizyme Inc. in its follow-on offering announced on January 12, 2016.

September 25, 2014

Q&A With WilmerHale’s Stuart Falber

A question and answer interview with Stuart Falber, published in Law360 on September 25, 2014.

October 21, 2011

2011 M&A Report

Practices

Skip Navigation Links.

Education

JD, magna cum laude, University of Pennsylvania Law School, Order of the Coif; Senior Editor, University of Pennsylvania Law Review

BA, cum laude, Tufts University

Bar Admissions

Massachusetts

Skip Navigation Links.